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Open accAbstract Background: Adjuvant! Online is a free web-based tool which predicts 10-year
breast cancer outcomes and the efﬁcacy of adjuvant therapy in patients with breast cancer.
As its prognostic performance has only been validated in high income Caucasian populations,
we validated the model in a middle income Asian setting.
Methods: Within the University Malaya Hospital-Based Breast Cancer Registry, all 631
women who were surgically treated for invasive non-metastatic breast cancer between 1993
and 2000 were identiﬁed. The discriminative performance of Adjuvant! Online was tested
using receiver operating characteristic (ROC) analysis. Calibration of the model was evaluated
by comparing predicted 10-year overall survival with observed 10-year survival.
Findings: Adjuvant! Online was fairly capable in discriminating between good and poor
survivors, as attested by the area under ROC curve of 0.73 (95% Conﬁdence Interval: 0.69–
0.77). Overall, Adjuvant! Online predicted 10 year survival (70.3%) was signiﬁcantly higher
than the observed 10 year survival (63.6%, difference of 6.7%; 95% CI: 3.0–10.4%). The model
was especially overoptimistic in women under 40 years and in women of Malay ethnicity,
where survival was overestimated by approximately 20% (95% CI: 9.8–29.8%) and 15%
(95% CI: 5.3–24.5%) respectively.vision, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Tel.: +31
.
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N. Bhoo-Pathy et al. / European Journal of Cancer 48 (2012) 982–989 983Interpretation: Even though Adjuvant! Online is capable of discriminating between good and
poor survivors, it systematically overestimates survival. These ﬁndings suggest that the model
requires adaptation prior to use in Asian settings.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
In contrast to the West, where breast cancer incidence
rates have stabilised or even decreased,1–3 breast cancer
incidence4 and mortality5 have increased sharply in
Asian countries. Despite this disturbing trend, surpris-
ingly little research has addressed determinants of sur-
vival following breast cancer in Asia. Most prognostic
factors for breast cancer have been established in aﬄu-
ent Western settings. The validity of these prognostic
factors has hardly been evaluated in most other settings.
Adjuvant! Online for Breast Cancer is a free web-based
prognostication tool which was developed based on the
Surveillance, Epidemiology and End Results (SEER)
database and treatment eﬃcacy data from meta-analy-
ses.6 It estimates individual ten year survival probabili-
ties, and risks of relapse in patients with breast cancer,
based on their clinical characteristics and systemic treat-
ment. In addition, Adjuvant! Online helps to predict the
absolute beneﬁt of adjuvant therapy in individual
patients. Since its introduction in the early 2000s, Adju-
vant! Online has gained worldwide recognition among
clinicians as a tool to aid patient counselling and clinical
decision making for women with early breast cancer.7
The programme has been validated by several groups in
Canada and Europe.7–9 Two studies have shown that
the model accurately predicts survival probabilities
across most patient groups,7,8 whereas a study conducted
in the United Kingdom found that Adjuvant! Online sys-
tematically overestimated survival by about 5.5 percent.9
Little is known on the prognostic performance of
Adjuvant! Online in non-Western, low or middle income
settings. In multi-ethnic Asia, genetic backgrounds,
socio-economic proﬁles, lifestyles and cultures are sub-
stantially diﬀerent from those in the US and Europe,
and each of these factors may play a distinct role in
breast cancer prognosis and treatment. In fact, an
urgent need to validate Adjuvant! Online in diﬀerent
regions had been highlighted.10 Malaysia is a middle
income country in South East Asia comprising 3 major
ethnic groups i.e. Malays, Chinese and Indians.11
In the present study, we evaluated whether Adjuvant!
Online is a valid prognostic tool in a cohort of Malay-
sian women with early breast cancer.
2. Methods
Data from the University Malaya Medical Center
(UMMC) Breast Cancer Registry was used.12 UMMC
is an academic tertiary hospital situated in the relativelyaﬄuent part of Kuala Lumpur, Malaysia and caters to a
predominantly middle class urban population. The
UMMC Breast Cancer Registry is a prospective hospi-
tal-based database of 3795 consecutive women who were
newly diagnosed with breast cancer between 1993 and
2008. This registry has been approved by the institu-
tion’s ethical review committee and encompasses data
on patient’s demography (including age and ethnicity),
tumour characteristics (including pathological data on
tumour size, number of involved lymph nodes, tumour
grade based on the Modiﬁed Bloom and Richardson
classiﬁcation and oestrogen receptor status [determined
via immunohistochemical staining and positive when
>10% tumour cells stained positive]). Treatment data
include type of treatment (surgery, chemotherapy,
radiotherapy and hormone therapy), type of surgery
(mastectomy, breast conserving surgery), chemotherapy
regimen and type of hormone therapy.
Between 1993 and 2000, metastatic work up was per-
formed by means of chest X-ray and liver function test
in patients with clinical stage I and II disease, whereas
patients with clinical stage III breast cancer underwent
computed tomography of the abdomen and pelvis, and
a bone scan. During the above period, the treatment
protocol in UMMC for invasive non-metastatic breast
cancer was mastectomy and axillary clearance for larger
tumours, and breast conservation surgery followed by
radiotherapy for localised small tumours. Between
1993 and 1996, six cycles of intravenous cyclophospha-
mide: 500 mg/m2, methotrexate: 50 mg/m2 and 5-ﬂuoro-
uracil: 500 mg/m2 (CMF) three-weekly was the routine
chemotherapy regimen for all patients. Since 1997, six
cycles of 5-ﬂuorouracil: 500 mg/m2, epirubicin: 75 mg/
m2 and cyclophosphamide: 500 mg/m2 (FEC-75) three-
weekly was widely used. Other less commonly used
regimes include four cycles of intravenous adriamycin
60 mg/m2, cyclophosphamide 600 mg/m2 with paclitaxel
175 mg/m2 three-weekly (AC-Paclitaxel), and 6 cycles of
intravenous mitomycin, methotrexate and mitoxantrone
(given in a clinical trial). Tamoxifen was prescribed rou-
tinely for women with hormone-receptor positive breast
cancer and postmenopausal women with unknown hor-
mone receptor status.
For the present study, all 824 women who were newly
diagnosed with invasive non-metastatic breast cancer
between 1993 and 2000 (allowing at least 10 years of fol-
low-up) were identiﬁed. Patients were included if they
had undergone standard surgical treatment (i.e. mastec-
tomy or breast conserving surgery followed by radio-
therapy, n = 725). Women treated with neoadjuvant
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with missing information on tumour size and/or axillary
lymph node status (n = 38). The ﬁnal study population
consisted of 631 women.
Data on vital status and death were obtained from
the hospitals’ medical records, and by means of active
follow-up through the patients’ next-of-kin. In addition,
patients’ vital statuses were veriﬁed through direct link-
age with the National Registration Department in
Malaysia which has the mortality records of all Malay-
sians. In the current study, follow-up time was calcu-
lated for all patients, starting at the date of diagnosis
with breast cancer until death (all causes), date of last
contact (for those who emigrated or loss to follow-up)
or Nov 2010 (linkage with national mortality registry).
In this hospital based cancer registry, data on local or
systemic recurrences were not routinely available. Infor-
mation on co-morbidity was also incomplete.
For each patient, data on age (continuous), tumour
size (0.1–1.0 cm, 1.1–2.0 cm, 2.1–3.0 cm, 3.1–5.0 cm,
>5.0 cm), number of involved lymph-nodes (0, 1–3, 4–
9, >9 nodes), oestrogen-receptor status (positive, nega-
tive, undeﬁned) and tumour grade (grade 1, grade 2,
grade 3, undeﬁned) were manually entered into the
Adjuvant! Online (Version 80) programme. Type of
adjuvant chemotherapy was categorised as ﬁrst genera-
tion (CMF regime), or second generation (FEC-75,
AC-Paclitaxel, as well as mitomycin, methotrexate and
mitoxantrone). Third generation regimen was not
administered in our setting during the study period.
Hormone treatment was categorised as tamoxifen, aro-
matase inhibitors, tamoxifen for 2–3 years followed by
aromatase inhibitor for 2–3 years, ovarian ablation or
ovarian ablation plus tamoxifen (or other hormones).
Comorbidity was set at ‘average for age’ for all patients.
For every entry, Adjuvant! Online predicted ten-year
overall survival for four diﬀerent scenarios i.e. survival
without any adjuvant treatment, survival with adjuvant
chemotherapy only, survival with adjuvant hormone
therapy only and survival with both chemotherapy
and hormone therapy. The survival probability corre-
sponding to the actual treatment received by the patient
was recorded. An accuracy check, performed by recalcu-
lating Adjuvant! Online predicted survival probabilities
in a random sample of 100 patients showed minor devi-
ations in four patients resulting from wrong data entry.
3. Statistical analysis
Kaplan-Meier analysis was used to estimate the
observed ten year overall survival in the entire study
population and within subgroups. The mean predicted
ten year overall survival was calculated by averaging
the individual predicted survival probabilities derived
from Adjuvant! Online. To assess the calibration of
the Adjuvant! Online model, the observed and predicted
ten year overall survivals were compared using a one-sample t-test for proportions.7,8 This test was based on
the assumption that the Adjuvant! Online predicted sur-
vival was the true population value and thus ﬁxed.7
Observed 10 years survival probabilities were subse-
quently plotted against the means of deciles of Adju-
vant! Online predicted survival.
As Adjuvant! Online provides an estimate of survival
at a single time point i.e. 10-years, we used the receiver
operating characteristic (ROC) analysis. The Area under
the ROC Curve (AUC) gives an indication of the dis-
criminatory performance of the model, and can be inter-
preted as the proportion of patients who are correctly
predicted to be alive or dead at 10 years. An AUC of
0.5 indicates no discriminative performance while an
AUC of 1.0 indicates perfect discrimination. All statisti-
cal analyses were performed using SPSS for Windows
version 16.0 (SPSS Inc., Chicago, Illinois, USA).
4. Role of funding source
The study sponsor did not play any role in study
design; in the collection, analysis, and interpretation of
data; in the writing of the report and in the decision to
submit the paper for publication.5. Results
In this cohort of 631 Asian women with early breast
cancer, the median age at diagnosis was 49 years. The
majority of patients were Chinese (66.9%), followed by
Malays (16.8%), Indians (15.2%) and other races
(1.1%). The median tumour size at presentation was
30 cm and approximately half of the patients had
lymph node involvement. Oestrogen receptor status
and tumour grade were unknown in approximately
25% of the patients. Four-hundred-ﬁfty-eight (72.6%)
patients were given hormonal treatment, two (0.4%) of
which received aromatase inhibitors while the rest
received tamoxifen. Among 396 (62.8%) patients who
were given chemotherapy, 146 (36.9%) had received
CMF, 218 (55.1%) received FEC-75, 24(6.0%) received
AC-paclitaxel and 4 (1.0%) received mitomycin, metho-
trexate and mitoxantrone. Chemotherapy was unspeci-
ﬁed in four (1.0%) patients (Table 1).
Of the 631 patients, 225 women died within 10 years of
follow up (Fig. 1). Overall, Adjuvant! Online predicted
10-years overall survival was 70.3%, whereas the actual
observed 10-years overall survival was 63.6%, indicating
an overestimation of survival of 6.7% (95% CI: 3.0% to
10.4%). The model was especially overoptimistic in
patients aged less than 40 years at diagnosis (n = 96),
and in women of Malay ethnicity (n = 106), where sur-
vival was over-estimated by approximately 20% (95%
CI: 9.8–29.8%) and 15% (95% CI: 5.3–24.5%) respec-
tively. In patients with tumours smaller than 2 cm, lymph
node negative disease, oestrogen receptor positive
tumours and low grade tumours, observed and predicted
Table 1
Calibration of Adjuvant! Online in 631 South East Asian Women with Breast Cancer.
Number (%) Overall Survival (%)
Adjuvant! Predicted Observed (SE) Predicted–Observed (95% CI) P value
All patients 631 (100) 70.3 63.6 (1.9) 6.7 (3.0 to 10.4) <0.001
Year of diagnosis
1990–1995 225 (35.6) 67.9 59.1 (3.3) 8.8 (2.3 to 15.3) 0.008
1996–2000 406 (64.3) 71.7 66.2 (2.4) 5.5 (0.8 to 10.2) 0.022
Age (years)
<40 96 (15.1) 75.6 55.8 (5.1) 19.8 (9.8 to 29.8) <0.001
40–64.9 469 (74.3) 71.9 67.3 (2.2) 4.6 (3.7 to 8.9) 0.037
>=65 67 (10.6) 51.8 49.0 (6.2) 2.8 (–9.4 to 15.0) 0.653
Ethnicitya
Chinese 422 (67.6) 71.6 67.7 (2.3) 3.9 (–0.6 to 8.4) 0.091
Malay 106 (17.0) 71.2 56.3 (4.9) 14.9 (5.3 to 24.5) 0.003
Indians 96 (15.4) 64.9 55.5 (5.1) 9.4 (–0.6 to 19.4) 0.068
Tumour size
<2 123 (19.5) 81.5 80.0 (3.7) 1.5 (–5.8 to 8.8) 0.686
2–5 385 (61.0) 71.4 64.2 (2.5) 7.2 (2.3 to 12.1) 0.004
>5 123 (19.5) 55.8 45.9 (4.5) 9.9 (1.1 to 18.7) 0.030
Lymph node involvement
No 329 (52.1) 79.8 77.8 (2.3) 2.0 (–2.5 to 6.5) 0.385
Yes 302 (47.9) 60.0 48.5 (2.9) 11.5 (5.8 to 17.2) <0.001
Oestrogen receptor status
Negative 212 (33.6) 61.0 51.2 (3.5) 9.8 (2.9 to 16.7) 0.006
Positive 262 (41.5) 78.0 72.6 (2.8) 5.4 (–0.1 to 10.9) 0.055
Unknown 157 (24.9) 70.2 65.3 (3.8) 4.9 (–2.5 to 12.3) 0.199
Grade
Low 73 (11.6) 82.6 85.9 (4.1) –3.3 (–11.3 to 4.7) 0.424
Moderate 243 (38.5) 72.5 63.3 (3.1) 9.2 (3.1 to 15.3) 0.003
High 158 (25.0) 64.2 53.8 (4.0) 10.4 (2.6 to 18.2) 0.010
Unknown 157 (24.9) 67.5 63.7 (3.9) 3.8 (–3.8 to 11.4) 0.331
Chemotherapy
Yes 396 (62.8) 69.7 59.6 (2.5) 10.1 (5.2 to 15.0) <0.001
No 235 (37.2) 71.4 70.6 (3.0) 0.8 (-5.1 to 6.7) 0.790
Hormone therapy
Yes 458 (72.6) 72.1 66.3 (2.2) 5.8 (1.5 to 10.1) 0.009
No 173 (27.4) 65.7 56.5 (3.8) 9.2 (1.8 to 16.6) 0.017
a Excluding patients from other races (n = 7).
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Fig. 2 shows the observed 10-years survival probabilities
against the predicted 10-years survival from Adjuvant!
Online, and shows that the model systematically overesti-
mated survival for the entire range of predicted probabil-
ities. ROC analysis of the whole cohort showed that the
model discriminated fairly between good and poor survi-
vors with an AUC of 0.73 (95% CI: 0.69–0.77), and also
within the subgroups (Table 2).
In this study, 23 patients did not complete chemo-
therapy (received less than 4 cycles of CMF/FEC).When these patients were excluded, Adjuvant! Online
still overestimated survival, both in the overall cohort
(by 5.8%; 95% CI: 2.1–9.5%) and in the subgroup of
patients subjected to chemotherapy (by 9.5%; 95% CI:
4.6–14.5%). Since previous studies have excluded
patients with tumour size of more than 5 cm6–8, we
repeated the analysis excluding 123 patients with
tumours larger than 5 cm. The over-optimism of Adju-
vant! Online still persisted with a diﬀerence between
the predicted and observed 10-years overall survival of
5.9% (95% CI: 1.7–10.0%).
Fig. 2. Observed overall survival against Adjuvant! Online predicted overall survival in 631 South East Asian Women.
Fig. 1. Overall survival following breast cancer in 631 South-East Asian Women.
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approximately 25% of the study population, a sensitivity
analysis was conducted within 394 women whose ER
status and tumour grade were known. It was found that
Adjuvant! overestimated survival by 8.1% (95% CI: 3.2–
13.0%) in this subgroup.
6. Discussion
In this cohort of Asian patients, Adjuvant! Online
was capable of discriminating between good and poor
survivors, but it systematically overestimated survival.This overestimation was present in most subgroups
and especially obvious in the young (aged less than
40 years), as well as in patients of Malay ethnicity.
Adjuvant! Online is used in oncology practices not
only in the United States13,14 and Europe7,15 but also in
Asia.16 A study conducted in Hong Kong which assessed
the utility of Adjuvant! Online among a group of experi-
enced cancer specialists revealed that regular use of such
software for predicting breast cancer outcomes and treat-
ment beneﬁts resulted in a signiﬁcant impact on their clin-
ical decisions.16 To our knowledge, Adjuvant! Online for
breast cancer has never been validated in non-Western
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its clinical utility in such settings.Wedo acknowledge that
this study suﬀers from several limitations. Firstly, the
study sample is rather small, resulting in rather unstable
estimates in some subgroups. Furthermore, information
on breast cancer recurrences was incomplete, making it
impossible to study recurrence free survival. While
tumour grade and ER status were unknown in approxi-
mately 25% of our patients, this is unlikely to have inﬂu-
enced our results as a sensitivity analysis in women whose
ER status and tumour grade were known, revealed that
the main results remained essentially unchanged.
Discrepancies in the observed and Adjuvant! Online
predicted survival in the Asian setting may be partlyTable 2
Discriminatory Performance of Adjuvant! Online in 631 South East Asian
Number Area under curve
All patients 631 0.73
Age
<40 years 96 0.78
40–64 years 469 0.70
>=65 years 67 0.82
Ethnicity
Chinese 422 0.74
Malay 106 0.73
Indians 96 0.65
Tumour size
<2 cm 123 0.65
2–5 cm 385 0.71
>=5 cm 123 0.75
Lymph node involvement
Negative 329 0.65
Positive 302 0.71
Oestrogen receptor status
Negative 212 0.67
Positive 262 0.72
Unknown 157 0.77
Grade
Low 73 0.74
Moderate 243 0.74
High 158 0.63
Unknown 157 0.76
Chemotherapy
Yes 396 0.69
No 235 0.79
Hormone therapy
Yes 458 0.75
No 173 0.66
a 95% CI for area under curve that does not include 0.5 is considered asexplained by diﬀerences in life expectancy between our
study population and population in the United States
where the model was developed.17 However, this is unli-
kely to completely explain the observed discrepancies.
Other possible explanations include diﬀerences in
tumour biology, eﬀects of anti-cancer therapy, treatment
compliance and diﬀerences in lifestyle after cancer.
There is increasing evidence that tumour biology of
Asian patients is diﬀerent from that of Caucasian
women, as certain prognostic factors, such as HER2
expression, are more prevalent in Asian populations.18
In addition, the case-mix of the Asian population is dif-
ferent compared to the Western population.12,19 In Asia,
a higher proportion of young women are diagnosed withWomen.
95% Conﬁdence interval for Area under curvea
Lower limit Upper limit
0.69 0.77
0.69 0.88
0.66 0.75
0.72 0.92
0.69 0.79
0.63 0.82
0.54 0.76
0.54 0.76
0.65 0.76
0.66 0.83
0.59 0.72
0.65 0.76
0.60 0.74
0.65 0.79
0.69 0.84
0.60 0.89
0.68 0.81
0.54 0.71
0.68 0.84
0.64 0.74
0.72 0.85
0.70 0.79
0.58 0.74
statistically signiﬁcant.
988 N. Bhoo-Pathy et al. / European Journal of Cancer 48 (2012) 982–989breast cancer compared to their Caucasian counter-
parts19–21, and they are also more likely to present with
unfavourable tumour characteristics such as lymph node
involvement, large tumour size, and ER negative dis-
ease.12,22 In the current study, Adjuvant! Online per-
formed well in elderly women and in women with
favourable tumour characteristics (small size, lymph
node negative, oestrogen receptor positive and low
grade). These proﬁles represent the majority of breast
cancer patients in Caucasian settings22 and our results
suggest that Adjuvant! Online may be over ﬁtted to
Western populations.
Diﬀerences in response to systemic anticancer therapy
may also explain some of the discrepancy between
observed and predicted survival. The metabolism of anti-
cancer drugs for instance may diﬀer between individuals
due to presence of underlying genetic variations.23 In our
cohort, Adjuvant! Online was able to predict survival
accurately in the group not receiving chemotherapy,
whereas it overestimated survival in patients subjected
to chemotherapy by approximately ten percent. A recent
review looking at diﬀerences in toxicity and clinical
outcome following treatment with anticancer drugs high-
lighted that there may be ethnic diﬀerences in tolerability
and response to cytotoxic chemotherapy in breast cancer
suggesting that anti-cancer drugs may be more eﬀective
in certain ethnic groups.24 Given the presence of under-
lying pharmacogenomic diﬀerences in drug metabolism
and response, it is also plausible that a higher proportion
of breast cancer patients in our settings had been sub-
jected to reductions in chemotherapy relative dose inten-
sity due to toxicity,25 hence resulting in poorer survival.
Furthermore, non-adherence with adjuvant therapy
may be responsible for some of the diﬀerences in pre-
dicted and observed survival. Non-adherence in Asian
breast cancer patients can be attributed to ﬁnancial bar-
riers (in the absence of a health insurance schemes), and
socio-cultural factors such as lack of decision making
power, belief in alternative therapy and fatalistic
views.26,27 Cancer fatalism, i.e. the belief that death is
inevitable when one has cancer, has been hypothesised
to aﬀect cancer prevention behaviour and treatment
adherence.28 Exclusion of patients who did not complete
their chemotherapy treatment did not attenuate our
ﬁndings. However, data on hormone therapy adherence
was not available.
Lifestyle factors, such as diet and body weight, are
increasingly being recognised as important prognostic
factors of breast cancer.29 Owing to cultural and reli-
gious diﬀerences, lifestyle proﬁles of Asian women diﬀer
substantially within South East Asia. For instance, obes-
ity which is an unfavourable prognostic factor in breast
cancer,30 is more common in Malay and Indian women,
whereas the Chinese have the lowest body mass index.31
This factor could explain some of the overestimation inAdjuvant! Online predicted survival in Malay women,32
in whom survival was overestimated by almost 15%.
In conclusion, this is the ﬁrst study in a middle
income, non-Caucasian setting, showing that Adjuvant!
Online is capable of discriminating between good and
poor survivors after breast cancer in Asian women.
However, as the model is overoptimistic, we propose
to adapt Adjuvant! Online using a large multicentre
cohort of Asian breast cancer patients to improve its
utility in Asian settings.
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